IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.

@article{CarloStella2007IFNgammaET,
  title={IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.},
  author={C. Carlo-Stella and A. Guidetti and M. Di Nicola and C. Lavazza and L. Cleris and D. Sia and P. Longoni and M. Milanesi and M. Magni and Z. Nagy and P. Corradini and A. Carbone and F. Formelli and A. Gianni},
  journal={Cancer research},
  year={2007},
  volume={67 7},
  pages={
          3269-75
        }
}
To investigate the therapeutic activity of the fully human anti-HLA-DR antibody 1D09C3 in multiple myeloma (MM), we reevaluated HLA-DR expression on CD138(+) cells, analyzed the capacity of IFN-gamma to up-regulate HLA-DR expression on MM cell lines, and tested the in vitro and in vivo activity of 1D09C3 alone or in combination with IFN-gamma. CD138(+)HLA-DR(+) cells were detected in 31 of 60 patients, with 15 of 60 patients having >/=20% CD138(+)HLA-DR(+) cells (median, 50%; range, 23-100… Expand
Antibody-Based Therapies in Multiple Myeloma
Immunotherapy strategies in multiple myeloma.
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma
...
1
2
...

References

SHOWING 1-10 OF 58 REFERENCES
Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
...
1
2
3
4
5
...